Stoke Therapeutics Inc (STOK)

R&D Expense Growth

23.62%

Quarterly · Period ending:

STOK logo

STOK R&D Expense Growth

Latest reported23.62%
STOK Quarterly R&D Growth (QoQ) (0.00% → 23.62%)
High-resolution chart · PNG

STOK r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Stoke Therapeutics Inc R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
23.6181%
-3.9162%
10.8337%
44.0882%
-20.8746%
39.5039%
5.4853%
7.8541%
-5.5813%
3.0774%
7.7417%
-1.5346%
4.7599%
-6.9333%
3.7067%
9.2213%
-0.0332%
14.302%
10.0571%
1.8659%
42.187%
11.332%
9.8039%
1.7696%
10.4366%
1.7774%
8.7604%
8.2185%
45.7295%
37.5832%
34.89%
17.9555%
50.7987%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.